ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:11:34 2024-04-26 pm EDT 5-day change 1st Jan Change
1.05 CAD +3.96% Intraday chart for ZYUS Life Sciences Corporation +5.00% +16.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate MT
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets MT
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate MT
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee MT
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee CI
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care MT
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels MT
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels CI
ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023 CI
ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member, Wayne Brownlee and Announces Reconstitution of its Board Committees CI
ZYUS Life Sciences Initiated at Speculative Buy at Stifel GMP; Price Target Set at C$4.00 MT
ZYUS Life Sciences Corporation Strengthens Board of Directors with the Appointment of Wayne Brownlee CI
ZYUS Life Sciences Corporation Auditor Raises 'Going Concern' Doubt CI
ZYUS Life Sciences Inc. completed the acquisition of Phoenix Canada Oil Company Limited in a reverse merger transaction. CI
Phoenix Canada Oil Completes C$20.13-Milion Subscription Receipt Placement Ahead of Reverse Takeover MT
ZYUS Life Sciences Inc. announced that it has received CAD 20.130131 million in funding from Phoenix Canada Oil Company Limited CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ZYUS Life Sciences Corporation Auditor Raises 'Going Concern' Doubt CI
ZYUS Life Sciences Corporation announced that it has received $0.018557 million in funding CI
ZYUS Life Sciences Corporation announced a financing transaction CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chart ZYUS Life Sciences Corporation
More charts
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.05 CAD
Average target price
2.75 CAD
Spread / Average Target
+161.90%
Consensus
  1. Stock Market
  2. Equities
  3. ZYUS Stock
  4. News ZYUS Life Sciences Corporation
  5. ZYUS Life Sciences Initiated at Speculative Buy at Stifel GMP; Price Target Set at C$4.00